دورية أكاديمية

Opportunities for correction of immunosuppression in patients with COVID-19

التفاصيل البيبلوغرافية
العنوان: Opportunities for correction of immunosuppression in patients with COVID-19
المؤلفون: Mikhail V. Kiselevskiy, H. M. Treshalina, I. N. Mikhailova, D. V. Martirosyan, I. V. Manina, V. V. Reshetnikova, I. G. Kozlov
المصدر: Инфекция и иммунитет, Vol 12, Iss 4, Pp 651-658 (2022)
بيانات النشر: NIIÈM imeni Pastera, 2022.
Sankt-Peterburg , 2022.
سنة النشر: 2022
المجموعة: LCC:Infectious and parasitic diseases
مصطلحات موضوعية: covid-19, cytokine storm, t-cell response, immunocorrection therapy, il-2, Infectious and parasitic diseases, RC109-216
الوصف: Here, we review thematic publications in available literature sources of the databases PubMed, Scopus, Web of Science, eLibrary, 49 of which were dated of the years 19972022. Analysis of such reports is aimed at assessing features of cytokine storm-induced hyperinflammatory reaction with signs of immunosuppression accompanied by pronounced lymphopenia and lowered count of CD4+T helpers during severe COVID-19. The prognostic factor for unfavorable prognosis was based on the marker of systemic inflammatory reaction correlating with the disease severity the soluble IL-2 receptor as well as the neutrophil-to-lymphocyte ratio and the lymphocyte subset imbalance. An immunosuppressive therapy of severe forms of COVID-19, aimed at weakening the inflammatory response, exacerbates immune dysfunction by suppressing the T cell function, mainly due to Th1 lymphocytes involved in recognizing and eliminating intracellular pathogens particularly viruses. Upon that, cell-mediated immunity becomes compromised that relies on cytotoxic T-lymphocytes, natural killer cells and macrophages. Timely and targeted immunocorrection is required to prevent or reduce the immunosuppression that accompanies a severe disease course and leads to serious and prolonged complications, as well as to association of secondary infections. In fight against the cytokine storm, it is important not to miss a time point of developing immunosuppressive condition that transitions into immunoparalysis as follows from recent publications covering the tactics of treating immune-mediated complications of coronavirus infection. The review discusses opportunities for immunosuppressive therapy along with glucocorticosteroids and monoclonal antibodies blocking IL-6 or cognate receptors. Studies using mesenchymal stem cells (MSCs) to reduce systemic inflammatory response at COVID-19 are outlined in the review. The use of antigen-specific Treg and their combinations with antagonists of tumor necrosis factor- (TNF), interferon- (IFN) as well as low-dose IL-2 in patients with SARS-CoV-2 infection were analyzed. The prognostic perspectives for CAR-T cells and CAR-NK cells technology have been considered as novel therapeutic approaches aimed at training effector cells to recognize the surface SARS-CoV-2 virus spike-like (S) protein. The feasibility of a therapeutic approach is also emphasized by comparatively analyzed of efficacy of using IL-7 or IL-15 during lymphopenia in patients with COVID-19. Here, side effects complicating immunocorrection come to the fore. Critical evaluation of corrected immunosuppressive conditions in patients with COVID-19 in the post-COVID-19 period by using low-dose IL-2 therapy revealed its ability to repair cellular immune response. As a result, a low-dose IL-2 therapy is recommended as a cytokine replacement therapy in such patients with COVID-19 during hyper-to-hypo-inflammatory phase transition in immune response.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: Russian
تدمد: 2220-7619
2313-7398
99519232
Relation: https://iimmun.ru/iimm/article/viewFile/1917/1485; https://doaj.org/toc/2220-7619; https://doaj.org/toc/2313-7398
DOI: 10.15789/2220-7619-OFC-1917
URL الوصول: https://doaj.org/article/4f0f77bf6645426db1382ab99519232f
رقم الأكسشن: edsdoj.4f0f77bf6645426db1382ab99519232f
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:22207619
23137398
99519232
DOI:10.15789/2220-7619-OFC-1917